Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Multi-Center, Open-Label, Dose-Escalation Study to Determine the Pharmacokinetics and Safety of Pomalidomide When Given in Combination With Low Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma and Impaired Renal Function

NCT01575925 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT01575925
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01575925 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Multi-Center, Open-Label, Dose-Escalation Study to Determine the Pharmacokinetics and Safety of Pomalidomide When Given in Combination With Low Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma and Impaired Renal Function
Lead sponsor
Celgene
Phase
Phase 1
Overall status
Completed
Start date
June 1, 2012
Completion date
August 7, 2018
Enrollment
25 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, renal impairment